- FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
- Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
Published 2014 ( Spanish Society of Pathology) ( Spanish Society of Medical Oncology)
- Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma - (NICE technology appraisal guidance [TA269])
Published 2012 ( National Institute for Health and Care Excellence)
- A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment.
Published 2015 ( American College of Medical Genetics and Genomics) ( National Society of Genetic Counselors)
domingo, 9 de julio de 2017
Melanoma [NEW TOPIC PAGE]
From Guideline Database
This database contains updated guidelines, policies and recommendations on genomic research and practice, as provided by professional organizations, federal advisory groups, expert panels and policy groups.